資本剰余金、欠損填補、貸倒引当金戻入額他2件
- 【期間】
| 年度 | 資本剰余金 | 欠損填補 | 貸倒引当金戻入額 | 固定負債計 | 研究開発費 - 抗体関連事業 |
|---|
| 2008/03 | 14.2億 | | - | | - | | - | | - | |
| 2009/03 | 14.2億 | ±0% | - | | 1.1百万 | | 0.71億 | | - | |
| 2010/03 | 14.2億 | ±0% | - | | 1.9百万 | +80.6% | 0.49億 | -31.2% | - | |
| 2011/03 | 14.2億 | ±0% | - | | 0.69百万 | -63.7% | 0.88億 | +79.9% | - | |
| 2012/03 | 4.92億 | -65.3% | -925百万 | | - | | 0.55億 | -36.7% | - | |
| 2013/03 | 4.92億 | ±0% | - | | - | | 1.25億 | +125.3% | - | |
| 2014/03 | 8.78億 | +78.6% | - | | - | | 0.78億 | -37.5% | - | |
| 2015/03 | 8.78億 | ±0% | - | | - | | 2.85億 | +264.8% | - | |
| 2016/03 | 9.79億 | +11.4% | - | | - | | 4.05億 | +42.1% | - | |
| 2017/03 | 13億 | +33.3% | - | | - | | 18.5億 | +356.7% | - | |
| 2018/03 | 16.7億 | +27.9% | - | | - | | 9.75億 | -47.3% | - | |
| 2019/03 | 18.2億 | +9.4% | - | | - | | 2.92億 | -70% | - | |
| 2020/03 | 20.6億 | +13% | - | | - | | 0.27億 | -90.8% | - | |
| 2021/03 | 20.6億 | ±0% | - | | - | | 0.64億 | +138.1% | - | |
| 2022/03 | 20.6億 | ±0% | - | | - | | 1.09億 | +70.8% | 93百万 | |
| 2023/03 | 20.6億 | ±0% | - | | - | | 1.04億 | -4.8% | 99百万 | +6.3% |
| 2024/03 | 10.4億 | -49.5% | - | | - | | 0.95億 | -8% | 130百万 | +31% |
